药明康德出中报了:“营业总收入207.99亿元,同比去年增长20.64%,归母净利润为85.61亿元,同比去年增长101.92%,基本EPS为3.01元,平均ROE为14.44%。”营收增加20%,盈利增加100%,真的有点让人感觉恍惚了,CXO都能这么赚钱,那么搞创新药的是不是更赚钱呢?看了一下兰兰基金的净值,最近一年涨了70%,但是距离回到2021年的高点还要涨100%,问之前跌了多少?所以...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.